Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)

Market Cap	11.10B +76.7%
Revenue (ttm)	5.94B +28.1%
Net Income	2.49B -29.8%
EPS	31.33 -47.8%
Shares Out	81.61M
PE Ratio	4.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	802,215
Average Volume	865,663
Open	135.58
Previous Close	136.06
Day's Range	133.00 - 144.28
52-Week Range	68.72 - 143.75
Beta	0.56
RSI	72.82
Earnings Date	Jan 31, 2026

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 1,246
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INDSWFTLAB

Financial Performance

In fiscal year 2025, Ind-Swift Laboratories's revenue was 5.62 billion, a decrease of -67.13% compared to the previous year's 17.09 billion. Earnings were 2.50 billion, a decrease of -53.51%.